AMRN
AMARIN CORP PLCUKPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 25 ▼ Amarin reported Q4 2025 financial results showing a 21% year-over-ye…
- Mar 16 FDA: New REDUCE-IT Data in Patients at Extreme Cardiovascular R…
- Jun 4 ▼ The Supreme Court unanimously reversed the Federal Circuit, holding…
- Aug 24 FDA: New Analyses from REDUCE-IT® and EPA Mechanistic Data to b…
- Aug 28 FDA: New REDUCE-IT® Legacy Analysis Presented at European Socie…
- Oct 25 Amarin announced Phase 3 EMT2 trial results for VAZKEPA/VASCEPA (ico…
- Oct 25 FDA: Amarin Provides Update on University of Leeds Sponsored Ph…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Jan 31. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2026: 4 added (0 new), 6 trimmed or exited.
- Short sellersSTEADY
Short interest +1.0% to 537.9K shares. 7.6 days to cover, ≈2.6% of shares.
- TrendRANGE
9% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JANE STREET GROUP, LLC | TRIM | $322.5K |
| Steward Partners Investment Advisory, LLC | ADD | $149.2K |
| UBS Group AG | TRIM | $81.5K |
| BlackRock, Inc. | TRIM | $5.5K |
| CITIGROUP INC | NEAR_EXIT | $26.00 |
| MILLENNIUM MANAGEMENT LLC | TRIM | $1.8M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $771.0K |
| BlackRock, Inc. | TRIM | $13.7K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jun 2025Price is below the lowest target. Median implies +14%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Jun 25, 2025 | Goldman Sachs MAINTAIN | Sell |
| Apr 17, 2025 | Goldman Sachs MAINTAIN | Sell |
| Jun 20, 2024 | Cantor Fitzgerald REITERATE | Overweight |
| Jun 18, 2024 | Cantor Fitzgerald REITERATE | Overweight |
| Oct 25, 2023 | Jefferies DOWNGRADE | Hold |
| Jul 20, 2023 | Goldman Sachs MAINTAIN | Sell |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Fishman Peter L. SVP, CFO Aug 1, 2026 | EXERCISE | 313 sh |
Fishman Peter L. SVP, CFO Aug 1, 2026 | TAX W/H | $2.2K |
Fishman Peter L. SVP, CFO Aug 1, 2026 | AWARD | 313 sh |
Provoost Jonathan EVP, Chief Legal Officer Jul 1, 2026 | AWARD | 3,688 sh |
Provoost Jonathan EVP, Chief Legal Officer Jul 1, 2026 | TAX W/H | $20.1K |
Ketchum Steven B EVP, Chief Scientific Officer Jul 1, 2026 | AWARD | 3,688 sh |
Ketchum Steven B EVP, Chief Scientific Officer Jul 1, 2026 | TAX W/H | $30.1K |
Provoost Jonathan EVP, Chief Legal Officer Jul 1, 2026 | EXERCISE | 3,688 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $50.0M |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $183.4M |
| Next FY | None | None | No data | $189.0M |
Short side
FINRA· Oct 30, 2026SecBot reports
5 filings · 3 press releases · 0 bullish · 2 bearish · 3 neutral- NEUTRAL 8-KOct 28, 2026
Amarin reported Q3 2026 GAAP net income of $0.2M, its first profitable quarter in over two years…
The company achieved profitability on lower expenses, but top-line revenue continues to decline from generic pressure in the U.S. Watch for updates on the strategic review process with Barclays and…
- NEUTRAL PRESS-RELEASEOct 28, 2026
Amarin reported Q3 2026 net income of $0.2M, its first profitable quarter in over two years, on…
The strategic review with Barclays is the primary catalyst. Monitor for any announcement of a sale, partnership, or other transaction. The EMT2 Phase 3 data in colorectal cancer could open a new…
- MIXED PRESS RELEASEOct 25, 2026
Amarin announced Phase 3 EMT2 trial results for VAZKEPA/VASCEPA (icosapent ethyl) in colorectal…
The OS benefit is encouraging but the PFS miss complicates regulatory and commercial prospects for an oncology indication. Watch for Amarin's next steps on further analyses and potential discussions…
- NEUTRAL PRESS RELEASEAug 28, 2026
Amarin announced a post-hoc analysis from the REDUCE-IT trial at ESC 2026, showing that highly…
This is a scientific update with no immediate financial or regulatory impact. Traders should watch for any subsequent regulatory or commercial developments, but this press release alone is unlikely…
All AMRN filing & press-release reports (8)
- 8-K reportOct 28, 2026
- PRESS-RELEASE reportOct 28, 2026
- PRESS-RELEASE reportOct 25, 2026
- PRESS-RELEASE reportAug 28, 2026
- COURT-RULING reportJun 4, 2026
- 8-K reportApr 29, 2026
- PRESS-RELEASE reportMar 16, 2026
- 8-K reportFeb 25, 2026